340B drug discount program tightened with new audit rules and patient protections

What it does

This bill strengthens the 340B drug discount program by tightening eligibility rules for who qualifies as a 'patient,' establishing clear requirements for 'prescribing providers,' and creating robust oversight of contract pharmacies. It also expands the program to allow certain covered entities (federally qualified health centers, critical access hospitals, sole community hospitals) to dispense drugs prescribed by outside providers if they referred the patient, subject to strict documentation and audit requirements. Additionally, it requires covered entities to maintain transparent patient financial assistance policies, prohibits certain debt collection practices, and imposes penalties on manufacturers who refuse to offer discounts or place improper conditions on purchases.

Why we flagged it

The bill's primary mechanism is tightening 340B eligibility and oversight (patient definitions, provider qualifications, contract pharmacy registration, audit triggers) while simultaneously expanding access for safety-net providers through referral arrangements and mandating patient financial assistance. It is fundamentally a regulatory tightening paired with targeted access expansion, not a simple deregulation or subsidy.

What the text implies

• The 35% referral-prescription threshold and audit triggers may incentivize covered entities to limit referral-based dispensing to stay below audit thresholds, potentially reducing patient access to the expanded benefit.
• Extensive documentation and auditing requirements (5-year record retention, annual attestations, manufacturer audits) create significant compliance burden; smaller safety-net providers may lack resources to meet these standards, concentrating program benefits at larger entities.
• The 'Community Vulnerability Score' standard for child sites uses CDC/ATSDR SVI data; if that index is not updated frequently or validated for healthcare access, it may exclude vulnerable areas and create geographic inequities in program participation.
• Contract pharmacy transparency requirements (public listing of all contract pharmacies, geographic distance, mail-order status) may expose competitive information and could enable manufacturers or competitors to target or restrict contract pharmacy networks.
• Debt collection prohibitions apply only to entities in subsections (L), (M), (N), (O)—FQHCs, critical access hospitals, sole community hospitals—leaving other covered entities (e.g., disproportionate-share hospitals, Ryan White clinics) without these protections, creating a two-tier system.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates concrete protections for low-income patients at safety-net providers—financial assistance requirements, debt collection prohibitions, and expanded access to discounted drugs through referral networks—which is a net benefit. However, the extensive new documentation, audit, and compliance burdens on covered entities may increase administrative costs that could be passed to patients or reduce provider participation, and the referral provision is narrowly limited to three entity typ

Who stands to gain

• Low-income and uninsured patients at federally qualified health centers, critical access hospitals,
• Safety-net providers meeting eligibility criteria (through expanded referral-based dispensing author

Named in the bill

Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Centers for Medicare & Medicaid Services (CMS), Pharmaceutical manufacturers (subject to new conditions on pricing and delivery), Federally qualified health centers (FQHCs), Critical access hospitals, Sole community hospitals, Contract pharmacies, Comptroller General of the United States

Where it stands

7 cosponsors: 4 Republicans, 3 Democrats.

• Jul 6, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 6, 2026 — Referred to House Committee on Education and Workforce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

9 lobbying clients named this bill on 9 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $4,312,972 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 89% of bills with at least one filing.

Scott Peters, the sponsor, reported $1,174,750 in PAC receipts in the 2026 cycle.

• Astrazeneca Pharmaceuticals Lp — $1,680,000 on 1 filing
• Novartis — $1,410,000 on 1 filing
• Planned Parenthood Federation of America Inc — $652,972 on 1 filing
• 340b Health — $240,000 on 1 filing
• University of Rochester — $220,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.